The immune checkpoint inhibitor ipilimumab inhibits cytotoxic T-lymphocyte associated protein 4 (CTLA4 or CD152) and renders exposed cancer cells sensitive to T-cell mediated destruction [2]. This evidence concerns the gene CTLA4 and cancer.